TITLE

Rasagiline and Parkinson's disease

PUB. DATE
November 2009
SOURCE
Travel Medicine Advisor;Nov2009 Supplement, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article focuses on a study regarding the role of rasagiline in the progress of Parkinson's disease. It notes that 1176 patients with untreated Parkinson's were randomized to rasagiline 1 mg or 2 mg per day for 72 weeks or placebo for 36 weeks followed by rasagiline for 36 weeks. Results show that patients who started with rasagiline have slower rate of worsening between weeks 12 and 36, less worsening of the score between baseline and week 72 and non-inferiority between weeks 48 and 72.
ACCESSION #
44834103

 

Related Articles

  • Merck Serono's Phase III Parkinson's trial meets endpoint.  // PharmaWatch: CNS;Mar2009, Vol. 8 Issue 3, p7 

    The article reports on the outcome of the Merck Serono's first Phase III Parkinson's trial of safinamide. It states that increasing the daily "ON" time in mid-to late stage Parkinson's disease patients with motor fluctuations by 1.3 hours, patients experience the best level of motor functioning....

  • Experimental therapies for Parkinson's disease: Why fake it? Katsnelson, Alla // Nature;8/11/2011, Vol. 476 Issue 7359, p142 

    The article focuses on sham brain surgery as a possible treatment for patients with Parkinson's disease. According to scientists, sham brain surgery is an expensive, potentially dangerous, and possibly unethical bit of biomedical theatrics. It mentions the case of Peggy Willocks, who was...

  • UTHSC findings may lead to new treatments for some Parkinson's patients.  // Fort Worth Business Press;2011 Research Texas Supplement, p18 

    The article reports on the findings of a study from the University of Texas Health Science Center in San Antonio which may provide developments in the treatment of patients with Parkinson's disease.

  • Altropane[sup ®] : O 587.  // Drugs in R&D;2002, Vol. 3 Issue 3, p188 

    Adis CommentsAltropane[sup ®] [O 587] is under Phase III clinical development with Boston Life Sciences as a SPECT imaging agent for detecting neurological signs and symptoms of Parkinson’s disease. This profile has been selected from R&D Insight™, a pharmaceutical intelligence...

  • Pramipexole + Levodopa in Parkinson's Disease: Is the Whole Greater than the Sum of its Parts? Nirenberg, Melissa J. // Neurology Alert;Mar2010, Vol. 28 Issue 7, p52 

    LEVODOPA AND DOPAMINE AGONISTS (DAS) ARE commonly used treatments for Parkinson's disease (PD). Although DAs tend to have more side effects than levodopa, they are often favored as initial therapy because this strategy delays the onset of motor complications such as wearing off and dyskinesias....

  • Pramipexole Extended Release. Chwieduk, Claudine M.; Curran, Monique P. // CNS Drugs;2010, Vol. 24 Issue 4, p327 

    Pramipexole extended release (ER) is a non-ergolinic dopamine receptor agonist available for use as a once-daily oral treatment for the signs and symptoms of early and advanced idiopathic Parkinson's disease. Once-daily pramipexole ER and three times-daily pramipexole immediate release (IR) have...

  • New Post-Hoc Analyses Examined Neupro(r) Effects on Pain, Depressed Mood, Apathy and Fatigue in Patients with Parkinson's Disease.  // Biomedical Market Newsletter;4/28/2012, Vol. 21, p1 

    Information about several abstracts related to the effects of Neupro, rotigotine transdermal on common nonmotor symptoms of Parkinson's disease (PD), presented at the 64th AAN Annual Meeting held in New Orleans, Louisiana is presented. The abstracts presented at the meeting include positive...

  • A Placebo-Controlled Trial of Pioglitazone in Subjects with NonAlcoholic Steatohepatitis. Robinson, Malcolm // Internal Medicine Alert;2/28/2007, Vol. 29 Issue 4, p27 

    Although often unrecognized, nonalcoholic steatohepatitis (NASH) is an increasingly common chronic liver disease that can progress to cirrhosis and hepatoma. Typical features associated with NASH include obesity, fatty liver disease, and type 2 diabetes mellitus. Proposed treatments have...

  • A NEW DRUG DELIVERY SYSTEM FOR PARKINSON'S PATIENTS THAT HELPS MANAGE THEIR TREMORS. Espay, Alberto; Collins, Dee // Cincinnati Magazine;Jan2011, Vol. 44 Issue 4, p68 

    The article focuses on the study on the use of levodopa, which is delivered in a gel by a pump that directs it into the small bowel and allowing the continued stimulation of dopamine receptors among patients with Parkinson's disease. Gastroenterologist Nathan Schmulewitz inserted the tube...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics